I am really grateful to the hon. Lady for giving way again. She will be aware that the Government’s accelerated access review last October recommended that NICE should review its whole health technology assessment processes and methods. Is she concerned that the review of Kadcyla and other drugs under the cancer drugs fund is happening before that review takes place? We might learn the lessons about how the review process needs to improve, but we will not benefit from them.
Breast Cancer Drugs
Proceeding contribution from
Norman Lamb
(Liberal Democrat)
in the House of Commons on Thursday, 26 January 2017.
It occurred during Backbench debate on Breast Cancer Drugs.
Type
Proceeding contribution
Reference
620 c507
Session
2016-17
Chamber / Committee
House of Commons chamber
Librarians' tools
Timestamp
2024-08-13 12:55:28 +0100
URI
http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012637000350
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012637000350
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2017-01-26/17012637000350